Role of miR‑200 family in brain metastases: A systematic review

Fotakopoulos,George; Georgakopoulou,Vasiliki Epameinondas; Spandidos,Demetrios A.; Papalexis,Petros; Angelopoulou,Efthalia; Aravantinou‑Fatorou,Aikaterini; Trakas,Nikolaos; Trakas,Ilias; Brotis,Alexandros G.

doi:10.3892/mco.2023.2611

Role of miR‑200 family in brain metastases: A systematic review

Authors:
- George Fotakopoulos
- Vasiliki Epameinondas Georgakopoulou
- Demetrios A. Spandidos
- Petros Papalexis
- Efthalia Angelopoulou
- Aikaterini Aravantinou‑Fatorou
- Nikolaos Trakas
- Ilias Trakas
- Alexandros G. Brotis
View Affiliations

Affiliations: Department of Neurosurgery, General University Hospital of Larissa, 41221 Larissa, Greece, Department of Infectious Diseases and COVID‑19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece, Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Department of Neurology, Eginitio University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece, Department of Biochemistry, Sismanogleio Hospital, 15126 Athens, Greece, Department of Neurosurgery, General University Hospital of Larissa, 41221 Larissa, Greece
Published online on: January 25, 2023 https://doi.org/10.3892/mco.2023.2611
Article Number: 15
Copyright: © Fotakopoulos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Brain metastasis (BM) represents the single most severe neurological complication of systemic cancer. The prognosis of patients with BM is poor, irrespective of the implemented treatment. The present study performed a systematic review of the literature using three online databases (PubMed, Scopus and Web of Science). Recently, a number of small RNA molecules, the microRNAs (miRNAs/miRs), have attracted increasing scientific attention. Members of the miR‑200 family, which includes five miRNAs (miR‑141, miR‑200a, miR‑200b, miR‑200c and miR‑429) appear to play pivotal roles in cancer initiation and metastasis. Indeed, a systematic review of the pertinent literature revealed that miR‑200 family members regulate the brain metastatic cascade, particularly by modulating epithelial‑to‑mesenchymal transition. That holds true for the major representatives of BM, including lung and breast cancer, as well as for other less frequent secondary lesions originating from melanoma and the gastrointestinal tract. Therefore, the miRNAs may serve as potential diagnostic and/or prognostic markers, and under specific circumstances, as invaluable therapeutic targets. However, the available clinical evidence is relatively limited. A number of studies have suggested that the miR‑200 family members are accurate prognostic markers of survival and resistance to chemotherapy in patients with breast cancer. Similarly, they may prove helpful in differentiating a metastatic lesion from a malignant glioma, or a hemangioblastoma from a renal cell carcinoma in patients with von Hippel Lindau syndrome, based on a cerebrospinal fluid sample. However, currently, there is no known therapeutic role for miR‑200 family members in the setting of BM.

View Figures

View References

1	Clouston PD, DeAngelis LM and Posner JB: The spectrum of neurological disease in patients with systemic cancer. Ann Neurol. 31:268–273. 1992.PubMed/NCBI View Article : Google Scholar
2	Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, et al: EFNS Guidelines on diagnosis and treatment of brain metastases: Report of an EFNS Task Force. Eur J Neurol. 13:674–681. 2006.PubMed/NCBI View Article : Google Scholar
3	Nussbaum ES, Djalilian HR, Cho KH and Hall WA: Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 78:1781–1788. 1996.PubMed/NCBI
4	Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS and Chang SD: Brain metastases. Nat Rev Dis Primers. 5(5)2019.PubMed/NCBI View Article : Google Scholar
5	Boire A, Brastianos PK, Garzia L and Valiente M: Brain metastasis. Nat Rev Cancer. 20:4–11. 2020.PubMed/NCBI View Article : Google Scholar
6	Gavrilovic IT and Posner JB: Brain metastases: Epidemiology and pathophysiology. J Neurooncol. 75:5–14. 2005.PubMed/NCBI View Article : Google Scholar
7	Fidler IJ: The biology of brain metastasis: Challenges for therapy. Cancer J. 21:284–293. 2015.PubMed/NCBI View Article : Google Scholar
8	Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, et al: A uniform system for microRNA annotation. RNA. 9:277–279. 2003.PubMed/NCBI View Article : Google Scholar
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
10	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005.PubMed/NCBI View Article : Google Scholar
11	Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol. 15:331–341. 2005.PubMed/NCBI View Article : Google Scholar
12	Sontheimer EJ and Carthew RW: Silence from within: Endogenous siRNAs and miRNAs. Cell. 122:9–12. 2005.PubMed/NCBI View Article : Google Scholar
13	Barbato S, Solaini G and Fabbri M: MicroRNAs in oncogenesis and tumor suppression. Int Rev Cell Mol Biol. 333:229–268. 2017.PubMed/NCBI View Article : Google Scholar
14	Frixa T, Donzelli S and Blandino G: Oncogenic MicroRNAs: Key players in malignant transformation. Cancers (Basel). 7:2466–2485. 2015.PubMed/NCBI View Article : Google Scholar
15	Li J, Zhang Z, Chen F, Hu T, Peng W, Gu Q and Sun Y: The diverse oncogenic and tumor suppressor roles of microRNA-105 in cancer. Front Oncol. 9(518)2019.PubMed/NCBI View Article : Google Scholar
16	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007.PubMed/NCBI View Article : Google Scholar
17	Zhou K, Liu M and Cao Y: New Insight into microRNA functions in cancer: Oncogene-microRNA-Tumor suppressor gene network. Front Mol Biosci. 4(46)2017.PubMed/NCBI View Article : Google Scholar
18	Koutsaki M, Libra M, Spandidos DA and Zaravinos A: The miR-200 family in ovarian cancer. Oncotarget. 8:66629–66640. 2017.PubMed/NCBI View Article : Google Scholar
19	Choi YC, Yoon S, Jeong Y, Yoon J and Baek K: Regulation of vascular endothelial growth factor signaling by miR-200b. Mol Cells. 32:77–82. 2011.PubMed/NCBI View Article : Google Scholar
20	Huang GL, Sun J, Lu Y, Liu Y, Cao H, Zhang H and Calin GA: MiR-200 family and cancer: From a meta-analysis view. Mol Aspects Med. 70:57–71. 2019.PubMed/NCBI View Article : Google Scholar
21	Humphries B and Yang C: The microRNA-200 family: Small molecules with novel roles in cancer development, progression and therapy. Oncotarget. 6:6472–6498. 2015.PubMed/NCBI View Article : Google Scholar
22	Langley RR and Fidler IJ: The biology of brain metastasis. Clin Chem. 59:180–189. 2013.PubMed/NCBI View Article : Google Scholar
23	Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S and Sahin O: miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 29:4297–4306. 2010.PubMed/NCBI View Article : Google Scholar
24	Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, et al: miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 9:25–35. 2011.PubMed/NCBI View Article : Google Scholar
25	Byun Y, Choi YC, Jeong Y, Lee G, Yoon S, Jeong Y, Yoon J and Baek K: MiR-200c downregulates HIF-1α and inhibits migration of lung cancer cells. Cell Mol Biol Lett. 24(28)2019.PubMed/NCBI View Article : Google Scholar
26	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008.PubMed/NCBI View Article : Google Scholar
27	Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 5(5241)2014.PubMed/NCBI View Article : Google Scholar
28	Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A and Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23:2140–2151. 2009.PubMed/NCBI View Article : Google Scholar
29	Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22:894–907. 2008.PubMed/NCBI View Article : Google Scholar
30	Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, et al: Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 4(2427)2013.PubMed/NCBI View Article : Google Scholar
31	Gravgaard KH, Lyng MB, Laenkholm AV, Søkilde R, Nielsen BS, Litman T and Ditzel HJ: The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat. 134:207–217. 2012.PubMed/NCBI View Article : Google Scholar
32	Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, et al: miR-141-Mediated regulation of brain metastasis from breast cancer. J Natl Cancer Inst. 108(djw026)2016.PubMed/NCBI View Article : Google Scholar
33	Duhachek-Muggy S and Zolkiewska A: ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer. BMC Cancer. 15(93)2015.PubMed/NCBI View Article : Google Scholar
34	Shao B, Wang X, Zhang L, Li D, Liu X, Song G, Cao H, Zhu J and Li H: Plasma microRNAs predict chemoresistance in patients with metastatic breast cancer. Technol Cancer Res Treat. 18(1533033819828709)2019.PubMed/NCBI View Article : Google Scholar
35	Schickel R, Park SM, Murmann AE and Peter ME: miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 38:908–915. 2010.PubMed/NCBI View Article : Google Scholar
36	Mueller DW, Rehli M and Bosserhoff AK: miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 129:1740–1751. 2009.PubMed/NCBI View Article : Google Scholar
37	Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 26:462–469. 2008.PubMed/NCBI View Article : Google Scholar
38	Elson-Schwab I, Lorentzen A and Marshall CJ: MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One. 5(e13176)2010.PubMed/NCBI View Article : Google Scholar
39	Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, et al: Suppression of MicroRNA 200 family expression by oncogenic KRAS Activation promotes cell survival and epithelial-mesenchymal transition in KRAS-Driven cancer. Mol Cell Biol. 36:2742–2754. 2016.PubMed/NCBI View Article : Google Scholar
40	Zhong X, Yu X, Wen X, Chen L and Gu N: Activation of the LINC00242/miR-141/FOXC1 axis underpins the development of gastric cancer. Cancer Cell Int. 20(272)2020.PubMed/NCBI View Article : Google Scholar
41	Youn YH, Byun HJ, Yoon JH, Park CH and Lee SK: Long Noncoding RNA N-BLR upregulates the migration and invasion of gastric adenocarcinoma. Gut Liver. 13:421–429. 2019.PubMed/NCBI View Article : Google Scholar
42	Kanchan RK, Siddiqui JA, Mahapatra S, Batra SK and Nasser MW: microRNAs orchestrate pathophysiology of breast cancer brain metastasis: Advances in therapy. Mol Cancer. 19(29)2020.PubMed/NCBI View Article : Google Scholar
43	Balachandran AA, Larcher LM, Chen S and Veedu RN: Therapeutically significant MicroRNAs in primary and metastatic brain malignancies. Cancers (Basel). 12(2534)2020.PubMed/NCBI View Article : Google Scholar
44	Ahn YH and Ko YH: Diagnostic and therapeutic implications of microRNAs in non-small cell lung cancer. Int J Mol Sci. 21(8782)2020.PubMed/NCBI View Article : Google Scholar
45	Peng L, Fu J and Ming Y: The miR-200 family: Multiple effects on gliomas. Cancer Manag Res. 10:1987–1992. 2018.PubMed/NCBI View Article : Google Scholar
46	Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S and Krichevsky AM: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol. 14:689–700. 2012.PubMed/NCBI View Article : Google Scholar
47	Venneti S, Boateng LA, Friedman JR, Baldwin DA, Tobias JW, Judkins AR, Mourelatos Z and Lal P: MiRNA-9 and MiRNA-200a distinguish hemangioblastomas from metastatic clear cell renal cell carcinomas in the CNS. Brain Pathol. 22:522–529. 2012.PubMed/NCBI View Article : Google Scholar
48	Minn YK, Lee DH, Hyung WJ, Kim JE, Choi J, Yang SH, Song H, Lim BJ and Kim SH: MicroRNA-200 family members and ZEB2 are associated with brain metastasis in gastric adenocarcinoma. Int J Oncol. 45:2403–2410. 2014.PubMed/NCBI View Article : Google Scholar
49	Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H and Burwinkel B: Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer. 140:176–187. 2017.PubMed/NCBI View Article : Google Scholar
50	Yu C, Wan H, Shan R, Wen W, Li J, Luo D and Wan R: The prognostic value of the MiR-200 family in colorectal cancer: A meta-analysis with 1882 patients. J Cancer. 10:4009–4016. 2019.PubMed/NCBI View Article : Google Scholar
51	Fu J, Rodova M, Nanta R, Meeker D, Van Veldhuizen PJ, Srivastava RK and Shankar S: NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol. 15:691–706. 2013.PubMed/NCBI View Article : Google Scholar